ES2079172T3 - Nuevo procedimiento de cristalizacion de sustancias organicas de origen esteroideo y compuestos asi obtenidos. - Google Patents

Nuevo procedimiento de cristalizacion de sustancias organicas de origen esteroideo y compuestos asi obtenidos.

Info

Publication number
ES2079172T3
ES2079172T3 ES92900237T ES92900237T ES2079172T3 ES 2079172 T3 ES2079172 T3 ES 2079172T3 ES 92900237 T ES92900237 T ES 92900237T ES 92900237 T ES92900237 T ES 92900237T ES 2079172 T3 ES2079172 T3 ES 2079172T3
Authority
ES
Spain
Prior art keywords
pct
crystallization
steroid
origin
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92900237T
Other languages
English (en)
Inventor
Michel Lanquetin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire Theramex SAM
Original Assignee
Laboratoire Theramex SAM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Theramex SAM filed Critical Laboratoire Theramex SAM
Application granted granted Critical
Publication of ES2079172T3 publication Critical patent/ES2079172T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0077—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN NUEVO PROCESO DE CRISTALIZACION DE SUSTANCIAS ORGANICAS Y EN PARTICULAR ESTEROIDIANAS. LA PRESENTE INVENCION TIENE ESPECIFICAMENTE COMO OBJETO UN PROCESO DE CRISTALIZACION QUE PERMITE SIN OPERACION MECANICA OBTENER UNA CLASE GRANULOMETRICA HOMOGENEA PREDETERMINABLE, QUE CONSISTE EN QUE SE DISUELVE UNA SUSTANCIA EN UNA MEZCLA TERNARIA FORMADA POR UN SOLVENTE LIPOFILO, POR UN SOLVENTE HIDROFILO Y POR UN AGENTE TENSIOACTIVO A UNA TEMPERATURA CERCANA A LA EBULLICION DESPUES SE DEJA QUE LA MEZCLA VUELVA A UNA TEMPERATURA EN LA QUE LA CRISTALIZACION SE INICIA Y SEPARA LOS CRISTALES FORMADOS. PRODUCCION DE PRINCIPIOS ACTIVOS FARMACEUTICOS.
ES92900237T 1990-11-12 1991-11-12 Nuevo procedimiento de cristalizacion de sustancias organicas de origen esteroideo y compuestos asi obtenidos. Expired - Lifetime ES2079172T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9013981A FR2668945B1 (fr) 1990-11-12 1990-11-12 Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.

Publications (1)

Publication Number Publication Date
ES2079172T3 true ES2079172T3 (es) 1996-01-01

Family

ID=9402062

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92900237T Expired - Lifetime ES2079172T3 (es) 1990-11-12 1991-11-12 Nuevo procedimiento de cristalizacion de sustancias organicas de origen esteroideo y compuestos asi obtenidos.

Country Status (17)

Country Link
US (1) US5266712A (es)
EP (1) EP0510167B1 (es)
JP (1) JP3281954B2 (es)
KR (1) KR100196895B1 (es)
AT (1) ATE126806T1 (es)
BR (1) BR9106012A (es)
CA (1) CA2073760C (es)
DE (1) DE69112379T2 (es)
DK (1) DK0510167T3 (es)
ES (1) ES2079172T3 (es)
FI (1) FI111545B (es)
FR (1) FR2668945B1 (es)
GR (1) GR3018117T3 (es)
HU (1) HU212780B (es)
LV (1) LV11183B (es)
RU (1) RU2126013C1 (es)
WO (1) WO1992008730A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776191B1 (fr) * 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
US6432936B1 (en) * 1999-01-20 2002-08-13 Wisconsin Alumni Research Foundation Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
BRPI0116793B8 (pt) * 2000-12-14 2021-05-25 Johnson & Johnson produtos de hormônio de esteróide e métodos para prepará-los
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
PL1670433T3 (pl) 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
CA2548281C (en) * 2003-12-09 2013-11-12 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
US20050192264A1 (en) * 2004-02-04 2005-09-01 Penfold Philip L. Slow release steroid composition
US20060058276A1 (en) * 2004-07-15 2006-03-16 Oded Friedman Processes for the preparation and purification of rocuronium bromide
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
EP1931682A2 (en) * 2006-08-03 2008-06-18 Teva Pharmaceutical Industries Ltd. Process for preparing clopidogrel bisulphate
CN101961311B (zh) * 2010-09-21 2012-11-21 中山大学 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
BR112014031914B1 (pt) * 2012-06-18 2021-12-14 Therapeuticsmd, Inc Formulação farmacêutica encapsulada para liberação intravaginal compreendendo estradiol e uso da mesma para o tratamento de atrofia vulvovaginal e de um sistoma associado, bem como de um estado urinário deficiente em estrogênio
CN112871079B (zh) * 2021-01-27 2023-05-16 丽江映华生物药业有限公司 醋酸诺美孕酮微粒的制备方法及制备装置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096744A (en) * 1932-10-27 1937-10-26 Schering Corp Hydrogenation products of follicle hormones and method of producing same
US2361847A (en) * 1937-09-04 1944-10-31 Schering Corp Aromatization of steroid compounds and more especially to the production of estrone-and estradiollike compounds and of their derivatives from delta 1, 2, 4, 5-androstadienol-17-one-3
US2897216A (en) * 1954-11-01 1959-07-28 Schering Corp Process for the preparation of steroidal dienes and intermediates obtained thereby
US3053865A (en) * 1958-03-19 1962-09-11 Merck & Co Inc Novel 16-alkyl and 16-alkylene steroids and processes
US3007923A (en) * 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
DE2323812A1 (de) * 1973-05-11 1974-11-28 Jenapharm Veb Verfahren zur herstellung von kohlensaeurederivaten der oestranreihe
GB1515284A (en) * 1974-05-21 1978-06-21 Gastaud J Pharmaceutical compositions containing progestogens derived from the 17-alpha-hydroxy-19-nor-progesterone series

Also Published As

Publication number Publication date
FI923188A0 (fi) 1992-07-10
WO1992008730A1 (fr) 1992-05-29
DE69112379D1 (de) 1995-09-28
FI111545B (fi) 2003-08-15
JPH05503305A (ja) 1993-06-03
CA2073760C (fr) 2003-09-23
LV11183A (lv) 1996-04-20
HU212780B (en) 1996-11-28
KR100196895B1 (ko) 1999-06-15
EP0510167B1 (fr) 1995-08-23
FR2668945A1 (fr) 1992-05-15
BR9106012A (pt) 1993-01-05
GR3018117T3 (en) 1996-02-29
ATE126806T1 (de) 1995-09-15
RU2126013C1 (ru) 1999-02-10
JP3281954B2 (ja) 2002-05-13
HUT61319A (en) 1992-12-28
CA2073760A1 (fr) 1992-05-13
EP0510167A1 (fr) 1992-10-28
FI923188A (fi) 1992-07-10
LV11183B (en) 1996-10-20
DK0510167T3 (da) 1996-01-02
DE69112379T2 (de) 1996-03-28
HU9202608D0 (en) 1992-10-28
US5266712A (en) 1993-11-30
FR2668945B1 (fr) 1993-02-19
KR927003617A (ko) 1992-12-18

Similar Documents

Publication Publication Date Title
ES2079172T3 (es) Nuevo procedimiento de cristalizacion de sustancias organicas de origen esteroideo y compuestos asi obtenidos.
CO5011099A1 (es) Formulaciones en polvo en estado cristalino estable
PT99168A (pt) Processo para a producao de uma preparacao farmaceutica para ser administrativa oralmente, contendo nomeadamente um mono- ou dinitrato de isosorbida
SK286488B6 (sk) Spôsob výroby polymorfnej formy I a II 17ß-(N-terc.butylkarbamoyl)-4-aza-5alfa-androst-1-en-3-onu
KR900013950A (ko) (7α,17α)-17-히드록시-7-메틸-19-노르-17-프레근-5(10)-엔-20-인-3-온 화합물 및 약학적 담체를 함유한 약학적 조성물
MY126071A (en) Crystalline form ii of cabergoline.
CO4480032A1 (es) Cristales de glicosidos de espiroestanilo
JPS61122284A (ja) ベンヂチアジンジオキシド塩の新規結晶型
SE8204273L (sv) Forfarande for rening av beta-sitosterol isolerad fran neutralemnet i sulfatcellulosaprocessens rasapa
CA1064944A (en) Process for the preparation of n-(1-ethyl 2-pyrrolidyl methyl)-2-methoxy-5-sulfamoyl benzamide
Yershov et al. Preparation of gallium arsenide films on insulators by artificial epitaxy
EP0939068A4 (es)
Meikle Synthesis of 1, 2, 3, 4, 5-Tetrachlorobenzene-1-Cl36
US2787616A (en) Preparation of veratrum viride
JPS549257A (en) Preparation of highly pure 1,8-dihydroanthraquinone
JPS5478377A (en) Method and apparatus for growing semiconductor crystal
TH50813B (th) แม็คโครไลด์ที่เป็นผลึก
Adams et al. 2, 4-and 4, 6-Dinitro-and Diamino-m-xylenes
TH40675A (th) แม็คโครไลด์ที่เป็นผลึก
PT100315A (pt) Processo para a cristalizacao de substancias organicas de origem esteroidiana e os compostos assim obtidos
JPS5283750A (en) Crystals of 5-amino-4-imidazol-carboxyamide
CA2397594A1 (en) Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one
CA2132417A1 (en) A crystalline modification of 2,4-dioxo-6-methyl-1, 2,3,4-tetrahydropyrimidine, a method for the preparation thereof and a medical preparation based on it
JPS53110969A (en) Forming method for crystal
PL40159B1 (es)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 510167

Country of ref document: ES